Oral Semaglutide (Rybelsus) for Type 2 Diabetes

Date: October 21, 2019
Issue #: 
1583Summary: 
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus–
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a subcutaneously-injected formulation(Ozempic)
since 2017, is the first GLP-1 receptor agonist to
become available for oral administration; the 4 other
GLP-1 receptor agonists currently available in the US
are administered by subcutaneous (SC) injection.

Source: The Medical Letter - September 27, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Adlyxine Bydureon Byetta dulaglutide Exenatide Glucophage Liraglutide lixisenatide Metformin Ozempic Rybelsus semaglutide Trulicity type 2 diabetes Source Type: research